Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on July 17, 2026 reporting Item 8.01 (Other Events), Item 3.02 (Unregistered Sales of Equity Securities). Item 3.02 points investors to Item 8.01 for details on unregistered share issuance.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.02 · Unregistered Sales of Equity Securities
- Item 3.02 points investors to Item 8.01 for details on unregistered share issuance
- Share issuance terms, transaction size, and dilution implications require review of the referenced Item 8.01 disclosure
Item 8.01 · Other Events
- $23M of 8.00% convertible notes exchanged for approximately 5.0M shares and $23M cash
- $10.5M of notes separately converted into approximately 3.6M shares
- All 2028 Notes due 2028 eliminated, removing future 8.00% interest and maturity obligations
- Cash consideration funded from on-hand liquidity, reducing cash while simplifying the capital structure
- Approximately 8.6M shares issued, creating dilution for existing shareholders; shares privately placed under Securities Act exemptions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.